pipeline-prospector-insert
X

Find Neurology Drugs in Phase III Clinical Development in UNITED KINGDOM

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cannabidiol

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 31, 2020

            Details:

            U.S. FDA has accepted for filing with Priority Review its recently submitted supplemental New Drug Application for the use of EPIDIOLEX CV to treat seizures in Tuberous Sclerosis Complex.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Remimazolam

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cosmo Pharmaceuticals

            Deal Size: $143.2 million Upfront Cash: $11.1 million

            Deal Type: Licensing Agreement January 09, 2020

            Details:

            Acacia Pharma will be responsible for the marketing and distribution of ByFavo in the US in the context of its equity-for-product strategy.